Structural Modification of the Macrolide Brefeldin A to Analogues with Enhanced Cytotoxicity against KB Cells
DOI:
https://doi.org/10.48048/tis.2021.44Keywords:
Brefeldin A, Synthetic analogues, Cytotoxicity, BioactivityAbstract
The macrolide brefeldin A (BFA, 1) exhibited high cytotoxicity against KB cells. However, it was also toxic against non-cancerous cells. In order to lower toxicity against normal cells while maintaining the cytotoxic potency to the cancer cells, structural modification of this compound was undertaken. Starting from compound 1, the analogues 2-13 were synthesized and evaluated for cytotoxicity against KB cells. The analogue 2 exhibited the most potent cytotoxicity against KB cells, with an IC50 value of 0.034 nM, 67-fold more active than its parent compound 1. It was 41764 and 8235 fold more active than the standard drugs ellipticine and doxorubicin, respectively. The higher cytotoxicity against KB cells and lower toxicity against Vero cells of analogue 2 than those of the parent compound 1 contributed to its exceptionally high selectivity index of 9117. The results suggested that this analogue might be utilized to develop a new candidate for an anticancer drug.
HIGHLIGHTS
- Oral cancer is a major worldwide public health issue and may affect any oral cavity region, including the lips, tongue, mouth and throat
- The ester analogues (2-13) were the first report of the cytotoxic against human epidermoid carcinoma (KB) cells
- 7-O-acetyl BFA (2) exhibited the most potent cytotoxicity against KB cells, with an IC50 value of 034 nM, 67-fold more active than its parent compound 1
- The essentially structural features for the macrolide of BFA-type to exhibit high cytotoxicity against KB cells are the presence of a free hydroxyl group at the 4-position, a free hydroxyl group or the corresponding ester at the 7-position, and unsaturated functions at the 2- and 10-positions
GRAPHICAL ABSTRACT
Downloads
Metrics
References
VL Singleton, N Bohonos and AJ Ullstrup. Decumbin, a new compound from a species of Penicillium. Nature 1958; 181, 1072-3.
E Haerri, W Loeffler, HP Sigg, H Stähelin and C Tamm. Über die isolierung neuer Stoffwechselprodukte aus Penicillium brefeldianum DODGE. Helv. Chim. Acta 1963; 46, 1235-43.
GP Miao, J Han, KG Zhang, SC Wang and CR Wang. Protection of melon against Fusarium wilt-root knot nematode complex by endophytic fungi Penicillium brefeldianum HS-1. Symbiosis 2019; 77, 83-9.
V Betina, P Nemec, J Dobias and Z Baráth. Cyanein, a new antibiotic from Penicillium cyaneum. Folia. Microbiol. 1962; 7, 353-7.
Y Suzuki, H Tanaka, H Aoki and T Tamura. Ascotoxin (decumbin), a metabolite of Ascochyta imperfecta PECK. Agr. Biol. Chem. 1970; 34, 395-413.
M Chinworrungsee, S Wiyakrutta, N Sriubolmas, P Chuailua and A Suksamrarn. Cytotoxic activities of trichothecenes isolated from an endophytic fungus belonging to order hypocreales. Arch. Pharm. Res. 2008; 31, 611.
K Trisuwan, V Rukachaisirikul, Y Sukpondma, S Phongpaichit, S Preedanon and J Sakayaroj. Lactone derivatives from the marine-derived fungus Penicillium sp. PSU-F44. Chem. Pharm. Bull. 2009; 57, 1100-2.
YJ Wang, YF Wu, F Xue, ZX Wu, YP Xue, YG Zheng and YC Shen. Isolation of brefeldin A from Eupenicillium brefeldianum broth using macroporous resin adsorption chromatography. J. Chromatogr. B 2012; 895-896, 146-53.
Z Hu, L Qin, W Ding, Y Liu and Z Ma. New analogues of brefeldin A from sediment-derived fungus Penicillium sp. DT-F29. Nat. Prod. Res. 2016; 30, 2311-5.
J Xie, YY Wu, TY Zhang, MY Zhang, WW Zhu, EA Gullen, ZJ Wang, YC Cheng and YX Zhang. New and bioactive natural products from an endophyte of Panax notoginseng. RSC Adv. 2017; 7, 38100-9.
V Betina. Biological effects of the antibiotic brefeldin A (Decumbin, cyanein, ascotoxin, synergisidin): A retrospective. Folia Microbiol. 1992; 37, 3-11.
L Zhou, W Gao, K Wang, Z Huang, L Zhang, Z Zhang, J Zhou, EC Nice and C Huang. Brefeldin A inhibits colorectal cancer growth by triggering Bip/Akt-regulated autophagy. FASEB J. 2019; 33, 5520-34.
H Huang, T Liu, J Guo, L Yu, X Wu, Y He, D Li, J Liu, K Zhang, X Zheng and S Goodin. Brefeldin A enhances docetaxel-induced growth inhibition and apoptosis in prostate cancer cells in monolayer and 3D cultures. Bioorg. Med. Chem. Lett. 2017; 27, 2286-91.
SA Lee, YJ Kim and CS Lee. Brefeldin A induces apoptosis by activating the mitochondrial and death receptor pathways and inhibits focal adhesion kinase-mediated cell invasion. Basic Clin. Pharmacol. Toxicol. 2013; 113, 329-38.
AB Argade, R Devraj, JA Vroman, RD Haugwitz, M Hollingshead and M Cushman. Design and synthesis of Brefeldin A sulfide derivatives as prodrug candidates with enhanced aqueous solubilities. J. Med. Chem. 1998; 41, 3337-46.
AB Argade, RD Haugwitz, R Devraj, J Kozlowski, PE Fanwick and M Cushman. Highly efficient diastereoselective michael addition of various thiols to (+)-Brefeldin A. J. Org. Chem. 1998; 63, 273-8.
BM Fox, JA Vroman, PE Fanwick and M Cushman. Preparation and evaluation of sulfide derivatives of the antibiotic Brefeldin A as potential prodrug candidates with enhanced aqueous solubilities. J. Med. Chem. 2001; 44, 3915-24.
L Renault, B Guibert and J Cherfils. Structural snapshots of the mechanism and inhibition of a guanine nucleotide exchange factor. Nature 2003; 426, 525-30.
Y Pommier and J Cherfils. Interfacial inhibition of macromolecular interactions: Nature's paradigm for drug discovery. Trends Pharmacol. Sci. 2005; 26,138-45.
H Sung, J Ferlay, RL Siegel, M Laversanne, I Soerjomataram, A Jemal and F Bray. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 2021; 71, 209-49.
World Health Organization. The global cancer observatory (GCO), Available at: https://gco.iarc.fr/today/data/factsheets/populations/764-thailand-fact-sheets.pdf, accessed May 2021.
A Miranda-Filho and F Bray. Global patterns and trends in cancers of the lip, tongue and mouth. Oral Oncol. 2020; 102, 104551.
JW Zhu, H Hori, H Nojiri, T Tsukuda and Z Taira. Synthesis and activity of Brefeldin A analogs as inducers of cancer cell differentiation and apoptosis. Bioorg. Med. Chem. Lett. 1997; 7, 139-44.
JW Zhu, H Nagasawa, F Nagura, SB Mohamad, Y Uto, K Ohkura and H Hori. Elucidation of strict structural requirements of Brefeldin A as an inducer of differentiation and apoptosis. Bioorg. Med. Chem. 2000; 8, 455-63.
B Proksa, D Uhrin, J Adamcova and J Fuska. Oxidation of Brefeldin A. Pharmazie 1992; 47, 582-4.
M Shibazaki, H Yamaguchi, T Sugawara, K Suzuki and T Yamamoyo. Microbial glycosylation and acetylation of Brefeldin A. J. Biosci. Bioeng. 2003; 96, 344-8.
NO Anadu, VJ Davisson and M Cushman. Synthesis and anticancer activity of Brefeldin A ester derivatives. J. Med. Chem. 2006; 49, 3897-905.
K Tian, F Xu, X Gao, T Han, J Li, H Pan, L Zang, D Li, Z Li and T Uchita. Nitric oxide-releasing derivatives of Brefeldin A as potent and highly selective anticancer agents. Eur. J. Med. Chem. 2017; 136, 131-43.
B He, Y Wang, Y Zheng, W Chen and Q Zhu. Synthesis and cytotoxic evaluation of acylated Brefeldin A derivatives as potential anticancer agents. Chem. Biol. Drug. Des. 2013; 82, 307-16.
K Seehafer, F Rominger, G Helmchen, M Langhans, DG Robinson, B Oezata, B Bruegger, JR Strating, FJ van Kuppeveld and CD Klein. Synthesis and biological properties of novel Brefeldin A analogues. J. Med. Chem. 2013; 56, 5872-84.
J O’Brien, I Wilson, T Orton and F Pognan. Investigation of the alamar blue (resazurin) fluorescent dye for the assessment of mammalian cell cytotoxicity. Eur. J. Biochem. 2000; 267, 5421-6.
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
